Methylomic biomarkers of lithium response in bipolar disorder: a clinical utility study.

ABSTRACT:

Background

Response to lithium (Li) is highly variable in bipolar disorders (BD). Despite decades of research, no clinical predictor(s) of response to Li prophylaxis have been consistently identified. Recently, we developed epigenetic Methylation Specific High-Resolution Melting (MS-HRM) assays able to discriminate good responders (GR) from non-responders (NR) to Li in individuals with BD type 1 (BD-I). This study examined whether a combination of clinical and epigenetic markers can distinguish NR from other types of Li responders.

Methods

We recorded clinical variables that are potentially associated with Li response in 64 individuals with BD-I. MS-HRM assays were performed on DNA isolated from peripheral blood. We used backward stepwise logistic regression analyses, follow

SUBMITTER: Marie-Claire C 

PROVIDER: S-EPMC10148930 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature